Clinical Trial Update: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS) [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial tests natalizumab for inflammatory demyelination suggestive of multiple sclerosis or definite multiple sclerosis at first presentati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinically Isolated Syndrome
• Multiple Sclerosis

Drugs mentioned

• Natalizumab (natalizumab)

Snippet

Sponsor: Queen Mary University of London | Conditions: Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination | Phase 2 | Status: RECRUITING